meta
|
evidence
COVID-19
Living systematic review and meta-analysis
***** adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
***** miscellaneous
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance